Diagnostic device maker Echosens is teaming up with the NASH Network and the Kinetix Group to develop a real-world evidence framework to help standardize delivery and optimize care for patients with nonalcoholic steatohepatitis. Paris-based Echosens markets FibroScan, a noninvasive device that quantitatively measures liver stiffness and fat using a gel probe, as well as the FibroMeter blood test, which checks for liver fibrosis and cirrhosis. The Kinetix Group consultancy firm focuses on helping life science companies integrate the use of real-world evidence, including working with health systems and payers to build value-based delivery models.
